Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SAGE THERAPEUTICS, INC.

(SAGE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Sage Therapeutics, Inc.
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.

Number of employees : 298 people.
Sales per Business
20192020Delta
USD (in Million)%USD (in Million)%
Novel Medicines6.87100%1,114100% +16123.06%
Sales per region
20192020Delta
USD (in Million)%USD (in Million)%
United States6.87100%1,114100% +16123.06%
Managers
NameAgeSinceTitle
Barry Greene562020President, Chief Executive Officer & Director
Kimi Iguchi57-Chief Financial Officer & Treasurer
Albert Robichaud592011Chief Scientific Officer
James Doherty-2017Chief Research Officer
Stephen Kanes552013Chief Medical Officer
Amy Schacterle-2020Senior VP-Research & Development Strategy
Kevin Starr572013Chairman
Steven Paul692014Independent Director
James M. Frates522014Independent Director
Michael F. Cola602014Independent Director
Members of the board
NameAgeSinceTitle
Kevin Starr572013Chairman
Steven Paul692014Independent Director
Jeffrey Jonas672020Director & Chief Innovation Officer
James M. Frates522014Independent Director
Michael F. Cola602014Independent Director
Geno J. Germano592016Independent Director
Elizabeth Barrett572019Independent Director
George S. Golumbeski, Dr.622019Independent Director
Barry Greene562020President, Chief Executive Officer & Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 58,483,051 51,283,376 87.7% 3,033 0.0% 87.7%
Shareholders
NameEquities%
Fidelity Management & Research Co. LLC 8,693,689 14.9%
Biogen Inc. 6,241,473 10.7%
Wellington Management Co. LLP 5,165,789 8.83%
The Vanguard Group, Inc. 4,678,260 8.00%
T. Rowe Price Associates, Inc. (Investment Management) 2,406,847 4.12%
Janus Capital Management LLC 1,873,382 3.20%
D. E. Shaw & Co. LP 1,871,875 3.20%
Bellevue Asset Management AG 1,810,704 3.10%
Artisan Partners LP 1,561,573 2.67%
OppenheimerFunds, Inc. 1,443,145 2.47%
Company contact information
SAGE Therapeutics, Inc.
215 1st Street
Cambridge, MA 02142

Phone : +1.617.299.8380
Fax : +1.617.299.8379
Web : http://www.sagerx.com
Sector Other Biotechnology & Medical Research
1st jan.Capitalization (M$)
SAGE THERAPEUTICS, INC.-34.30%3 326
MODERNA, INC.90.67%79 980
LONZA GROUP LTD14.63%52 508
IQVIA HOLDINGS INC.33.76%45 934
CELLTRION, INC.-24.79%32 465
SEAGEN INC.-10.75%28 367
HANGZHOU TIGERMED CONSULTING CO., LTD14.49%24 102
PHARMARON BEIJING CO., LTD.62.65%23 432
CUREVAC N.V.-23.60%21 497
ALNYLAM PHARMACEUTICALS, INC.36.10%20 793
INCYTE CORPORATION-4.43%18 465
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.43.19%17 774
BIO-TECHNE CORPORATION36.01%16 797
PPD, INC.35.36%16 288
NOVAVAX, INC.56.24%12 918
ICON PUBLIC LIMITED COMPANY8.82%11 215
PRA HEALTH SCIENCES, INC.33.28%10 833
QIAGEN N.V.-10.84%10 763
CRISPR THERAPEUTICS AG-16.51%10 242
GENSCRIPT BIOTECH CORPORATION191.22%8 779
SYNEOS HEALTH, INC.23.94%8 746